The antitumor effects of B7-H3 targeted CAR-T cells have also been frequently reported both in preclinical and in clinical trials for glioma (33), anaplastic meningioma (34), pediatric brain tumors (35), as well as lymphoma (36). This evidence concerns the gene CD276 and central nervous system cancer.